Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia.
about
A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophreniaThe chimeric gene CHRFAM7A, a partial duplication of the CHRNA7 gene, is a dominant negative regulator of α7*nAChR functionNeuregulin 1 and susceptibility to schizophrenia.Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes.Nootropic alpha7 nicotinic receptor allosteric modulator derived from GABAA receptor modulatorsEffect of Pharmacological Interventions on the Fronto-Cingulo-Parietal Cognitive Control Network in Psychiatric Disorders: A Transdiagnostic Systematic Review of fMRI StudiesModulatory effects of α7 nAChRs on the immune system and its relevance for CNS disordersThe human CHRNA7 and CHRFAM7A genes: A review of the genetics, regulation, and functionNicotinic acetylcholine receptor ligands, a patent review (2006-2011)α7 nicotinic ACh receptors as a ligand-gated source of Ca(2+) ions: the search for a Ca(2+) optimumInside-out neuropharmacology of nicotinic drugsPrenatal choline and the development of schizophreniaBrain-specific Crmp2 deletion leads to neuronal development deficits and behavioural impairments in miceInfluence of cigarette smoking on prepulse inhibition of the acoustic startle response in schizophreniaAttenuation of Compulsive-Like Behavior Through Positive Allosteric Modulation of α4β2 Nicotinic Acetylcholine Receptors in Non-Induced Compulsive-Like MiceIn vivo evaluation of alpha7 nicotinic acetylcholine receptor agonists [11C]A-582941 and [11C]A-844606 in mice and conscious monkeysA genome-wide RNAi screen in Caenorhabditis elegans identifies the nicotinic acetylcholine receptor subunit ACR-7 as an antipsychotic drug targetVarenicline Effects on Smoking, Cognition, and Psychiatric Symptoms in Schizophrenia: A Double-Blind Randomized TrialSpatial and intracellular relationships between the alpha7 nicotinic acetylcholine receptor and the vesicular acetylcholine transporter in the prefrontal cortex of rat and mousePresynaptic type III neuregulin1-ErbB signaling targets {alpha}7 nicotinic acetylcholine receptors to axonsSchizophrenia genes, gene expression, and neuropathology: on the matter of their convergencenAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: Current trends and perspectives.Chrna7 deficient mice manifest no consistent neuropsychiatric and behavioral phenotypes.Neuronal effects of nicotine during auditory selective attention in schizophreniaNicotinic ligands as multifunctional agents for the treatment of neuropsychiatric disordersMaximizing the effect of an α7 nicotinic receptor PAM in a mouse model of schizophrenia-like sensory inhibition deficits.Molecular substrates of schizophrenia: homeostatic signaling to connectivityR-(+) and S-(-) isomers of cotinine augment cholinergic responses in vitro and in vivo.Sensory processing dysfunction in the personal experience and neuronal machinery of schizophrenia.Cognitive deficits in schizophrenia: focus on neuronal nicotinic acetylcholine receptors and smoking.Translational utility of rodent hippocampal auditory gating in schizophrenia research: a review and evaluation.Cellular, molecular, and genetic substrates underlying the impact of nicotine on learning.Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia.Mouse models for studying genetic influences on factors determining smoking cessation success in humans.Effects of transdermal nicotine on episodic memory in non-smokers with and without schizophrenia.Event-related potential patterns associated with hyperarousal in Gulf War illness syndrome groups.Nicotinic mechanisms in the treatment of psychotic disorders: a focus on the α7 nicotinic receptorEffects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder.The developing utility of zebrafish models for cognitive enhancers researchMuscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia
P2860
Q21203917-F4006561-CB74-497B-A6B5-2D051B93464EQ24308763-EF9492A8-A0F6-4D4B-9279-C384DBA52C5DQ24616921-20E6CC21-CA01-4453-82CC-8720E8A36E64Q24631189-0772A612-ABA3-45AF-A267-5984365CE8F8Q24681828-A2427264-9DDC-48EB-8E07-D2FB59460F6DQ26744718-5BB26EA1-B922-46D0-84A8-46D73BA0119DQ26765419-EAAEEF24-9D00-4029-9B3A-F5E2FD38DDD9Q26821785-75C51E9F-6C55-4455-9CDE-C694A405A1C1Q26824360-0E39EA55-AF20-4CF5-8266-2D9828F9A1E8Q26852967-F034B6E3-2438-4788-92E1-A9D5C7EA7D98Q27010347-BA2962B4-BD75-4C80-A80F-E289FB5808F4Q27022263-47828024-AF37-4681-9981-E385D0A8227DQ27314818-3945C4AB-1B5B-4CD5-9515-83092288B28FQ28211739-F7270AAE-5E4E-4E66-A04B-06B9B1B62C2AQ28468423-C43FD4A3-D5BB-4726-B41F-1E9341971B6CQ28472724-F405559F-441B-40F8-86B1-7E8638E9E68CQ28487183-ACE0520A-82A8-4011-90BD-F3AA8A1E2E54Q28552053-35BF5A50-3F22-4B1C-92AE-16A9C9F46C60Q28573052-55979025-0E1F-4947-A482-2E8FB9EA2992Q28593522-4ACFFE42-E5D9-44F4-995C-A40B15A12050Q29618819-BCE5C1C4-618C-4313-8EA4-656BD818A39DQ30362464-D3561442-4C74-420A-A964-4D6E0DA083B3Q30366287-B22A2735-72C8-4929-9473-59A0D94CBEA4Q30366764-9B9CF122-D68D-4EB9-9F4D-250EC283F50DQ30372351-6E288AAA-018E-40BB-A7CA-AA230267851BQ30381001-52D375DE-24A4-4BDA-BFDA-E3EA9C78D991Q30383611-9D7E3F6E-6CCA-4BCF-9986-6730BF660BF6Q30392403-7FC6D795-2C89-4B98-8405-1F21CEE50A95Q30394589-A520EAAB-BE97-40D6-BC61-BD2A6F0BB6A8Q30396291-B384B223-F4FB-461B-88CF-2E7FBC505366Q30407039-0E08B9D0-95EA-4DD6-800F-AB052CE744DBQ30422037-156D280E-AB6A-4865-90AB-02847E1C70BBQ30428422-CE4F2AD9-5AC0-4221-B78D-4461551F5D16Q30432964-07279B06-D461-4FCC-848A-AF6DD9E17ED4Q30435496-2FDA0991-227D-472B-8539-246A6AC133A7Q30448790-BEDE634C-B19D-471C-B11A-032FC2E186E6Q30453198-4CEDF4CB-0A28-49C9-B21C-DA4A1BD3B5EEQ30455599-28E54134-7BF8-4BEF-9715-95D392025ECEQ30457705-A9A2AC8D-9771-4A0F-B1DC-827865A1D5A3Q30459624-4CEA5E6C-10B9-4E42-85D9-349BEE3B2056
P2860
Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Evidence in postmortem brain t ...... ic receptors in schizophrenia.
@en
type
label
Evidence in postmortem brain t ...... ic receptors in schizophrenia.
@en
prefLabel
Evidence in postmortem brain t ...... ic receptors in schizophrenia.
@en
P2093
P1476
Evidence in postmortem brain t ...... ic receptors in schizophrenia.
@en
P2093
P356
10.1016/0006-3223(94)00252-X
P407
P577
1995-07-01T00:00:00Z